

# INDEX

## A

- Active targeting ..... 7
- Adjuvants ..... 13, 137, 189, 190, 192, 193
- Allergens ..... 198
- Anaphylaxis ..... 11, 150, 161
- Antibodies ..... 7, 11, 29, 65–70, 138, 142, 143, 145, 149–151, 162, 165, 169, 173, 176, 178, 179, 182, 184, 186, 190, 191, 193, 204, 205, 208
- Antigens ..... 8, 13, 70, 149, 151, 162, 189–194, 198
- Autophagosomes ..... 211, 212, 218, 219
- Autophagy ..... 211–218

## B

- Bacteria ..... 10, 19–23, 31, 136, 143
- Bioanalytical ..... 99, 118
- Biodistribution ..... 10, 19, 163
- Biological matrices ..... 12, 37–47, 223
- Biology ..... 3, 7, 10–13, 242, 246
- Blood ..... 11, 12, 91–93, 95–98, 100, 101, 103–122, 137, 150, 155, 157, 159, 162, 164, 167, 168, 174, 175, 177, 184, 191, 225, 226, 228

## C

- C3 ..... 149–152, 159
- Charged aerosol detector (CAD) ..... 50–53
- Chemokines ..... 23, 173, 177
- Coagulation factors ..... 104, 105, 119, 121
- Colloidal metal nanoparticles ..... 58
- Complement ..... 12, 109, 125, 149–152, 154–157, 197
- Contamination ..... 10, 19–31, 82–84, 87, 143, 203
- Cryo-electron microscopy (Cryo-EM) ..... 73–75, 77, 80–83
- Cytokines ..... 23, 136, 137, 173–178, 180, 183–185, 187, 197

## D

- Displacement ..... 50, 52
- Disseminated intravascular coagulation (DIC) ..... 23, 104, 105
- Dissolution ..... 20, 38, 50–52, 54
- Drug release ..... 7, 9, 10, 12, 223, 241, 242

## E

- Efficacy ..... 5, 7, 8, 10, 12, 19, 24, 151, 190, 193, 241–251
- Electron microscope ..... 65–71, 73–75, 77–87, 212
- Emulsions ..... 5, 74, 82, 200
- Endotoxin ..... 10, 23–31, 104, 143, 173, 192
- Enzyme-linked immunoassay (EIA) ..... 151–153, 156

## F

- Fluorescence imaging ..... 212, 214, 215

## G

- Gold nanoparticles ..... 38, 49–51, 69, 100

## H

- Hemoglobin ..... 91–93, 95–98, 100
- Hemolysis ..... 12, 91–96, 98, 99, 158, 197
- Homogenization ..... 37–39
- Human cell line activation test (hCLAT) ..... 198–205, 207
- Hypersensitivity ..... 11, 151, 157, 161, 197–209

## I

- IL-1 $\beta$  ..... 136–140, 142–146, 174, 176, 178, 179, 185, 187
- Immune electron microscopy ..... 70
- Immunoassay ..... 151
- Immunostimulation ..... 173
- Immunosuppression ..... 11, 161, 163
- Indirect solid phase immunolabeling ..... 66
- Inductively coupled plasma mass spectrometry (ICP-MS) ..... 37–47
- Inflammasome ..... 135, 137–139, 142, 143, 145
- Inflammation ..... 10, 23, 24, 125, 137, 150, 173–178, 180, 183–185, 187
- Inhibition enhancement control (IEC) ..... 143, 177, 183–186
- Inorganic nanoparticles ..... 57
- Interference ..... 23–31, 92, 95, 100, 101, 114, 139, 142, 144, 145
- Interferon ..... 173–178, 180, 183–185, 187
- Irritant ..... 197

**L**

- Leukocyte procoagulant activity ..... 106, 116, 120, 121  
 Leukocyte proliferation..... 162, 163  
 Limulus ameocyte lysate (LAL) ..... 23–31, 143  
 Lipids ..... 5, 6, 12, 27, 37, 65, 74, 75, 80, 81, 86, 151  
 Liposomes..... 5–7, 9, 11, 27, 28, 65, 73–75, 77–87, 153, 200, 227, 228, 231, 232  
 Local lymph node assay (LLNA) ..... 198–200, 204, 206–208  
 Local lymph node proliferation (LLNP) ..... 198–200, 202, 204, 206–208  
 Lysosomal dysfunction ..... 242

**M**

- Microtubule-associated protein light chain  
   3-I (MAP LC3) ..... 212  
 Mold ..... 19  
 Myeloid U937 skin sensitization test  
   (MUSST) ..... 198–203, 205–207

**N**

- Nanoformulation ..... 3, 5, 8, 10–12, 23–31, 94, 105, 113, 120, 128, 137, 166, 191, 199, 241, 242, 244–247, 250, 251  
 Nanomaterials ..... 3, 10, 12, 13, 19–22, 24, 25, 27, 29–31, 66, 68–70, 93, 94, 99, 104, 105, 111, 113, 114, 126, 128, 137, 151, 162, 165–167, 176, 189–192, 197, 200, 203, 204, 211–214, 216, 218  
 Nanomedicines ..... 3–13, 174, 223, 241–251  
 Nanoparticles..... 3–13, 19–22, 38, 46, 49, 58, 65, 73, 92, 104, 125, 136, 151, 161, 174, 189, 199, 225, 241, 242, 244, 251  
 Negative staining..... 11, 65, 66, 69, 70, 73–81, 84, 85  
 NLRP3..... 135, 137–139, 142, 143, 145

**P**

- Passive targeting ..... 6–7  
 Phagocytosis ..... 125–129, 131, 132, 197  
 Plasma coagulation..... 104–109, 111, 112, 114–116, 119–121  
 Platelet aggregation ..... 104, 105, 107, 109, 111, 113, 114, 118, 120  
 Platelets..... 104, 105, 107, 109, 111, 113, 114, 118, 120, 122, 167  
 Polyethylene glycol (PEG) ..... 5, 6, 49–54, 65, 66, 94, 151

**R**

- Red blood cells (RBC)..... 91, 100

**S**

- Sensitizer..... 198  
 Stability ..... 5, 10, 12, 49, 174, 223, 231  
 Stable isotope ..... 12, 223  
 Statistical analysis ..... 131, 170, 192, 246  
 Subcutaneous ..... 151, 193, 198, 243, 244  
 Surface characterization ..... 10, 11, 104  
 Surface coatings..... 11, 57–63, 200

**T**

- T-cell dependent antibody response  
   (TDAR)..... 162, 163, 165, 167, 168, 170  
 Therapy ..... 3, 5–8, 12, 13, 94, 104, 108, 109, 128, 137, 150, 155, 161, 162, 166, 173, 174, 180, 197, 203, 211, 241, 246, 251  
 Thermogravimetric analysis (TGA)..... 11, 57  
 THP-1 ..... 137–141, 143, 198, 200, 204, 205  
 Thrombogenicity ..... 104  
 Thrombosis ..... 12, 104  
 Toxicity ..... 3, 5, 7, 10, 12, 19, 24, 65, 104, 137, 150, 162, 163, 198, 251  
 Transmission electron microscopy  
   (TEM)..... 11, 69, 73–75, 77–87  
 Tumor model ..... 242, 243, 251

**V**

- Vaccines..... 13, 137, 150, 151, 164, 168, 189, 190, 192

**W**

- Western blot ..... 137, 145, 151, 153  
 Whole blood..... 12, 91, 92, 95–97, 107, 109, 111, 174, 176, 180–183, 186

**Y**

- Yeast ..... 20, 211

**Z**

- Zymosan A ..... 126, 127, 131